AJANTA PHARMA | ELDER PHARMA | AJANTA PHARMA/ ELDER PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 24.4 | -0.2 | - | View Chart |
P/BV | x | 6.8 | 0.1 | 6,717.9% | View Chart |
Dividend Yield | % | 0.5 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AJANTA PHARMA Mar-19 |
ELDER PHARMA Jun-14 |
AJANTA PHARMA/ ELDER PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,422 | 380 | 374.2% | |
Low | Rs | 898 | 188 | 477.4% | |
Sales per share (Unadj.) | Rs | 233.5 | 491.2 | 47.5% | |
Earnings per share (Unadj.) | Rs | 44.0 | -3.2 | -1,381.8% | |
Cash flow per share (Unadj.) | Rs | 52.2 | 14.4 | 362.0% | |
Dividends per share (Unadj.) | Rs | 9.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 255.1 | 376.5 | 67.7% | |
Shares outstanding (eoy) | m | 88.02 | 20.54 | 428.5% | |
Bonus/Rights/Conversions | BB | - | - | ||
Price / Sales ratio | x | 5.0 | 0.6 | 859.0% | |
Avg P/E ratio | x | 26.4 | -89.3 | -29.6% | |
P/CF ratio (eoy) | x | 22.2 | 19.7 | 112.8% | |
Price / Book Value ratio | x | 4.5 | 0.8 | 602.8% | |
Dividend payout | % | 20.5 | 0 | - | |
Avg Mkt Cap | Rs m | 102,081 | 5,833 | 1,750.0% | |
No. of employees | `000 | 6.8 | NA | - | |
Total wages/salary | Rs m | 4,307 | 2,179 | 197.7% | |
Avg. sales/employee | Rs Th | 3,022.6 | NM | - | |
Avg. wages/employee | Rs Th | 633.4 | NM | - | |
Avg. net profit/employee | Rs Th | 569.1 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,554 | 10,089 | 203.7% | |
Other income | Rs m | 211 | 257 | 82.2% | |
Total revenues | Rs m | 20,765 | 10,346 | 200.7% | |
Gross profit | Rs m | 5,664 | -792 | -715.3% | |
Depreciation | Rs m | 721 | 361 | 199.5% | |
Interest | Rs m | 12 | 2,756 | 0.4% | |
Profit before tax | Rs m | 5,143 | -3,653 | -140.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 3,713 | 0.0% | |
Tax | Rs m | 1,273 | 125 | 1,017.2% | |
Profit after tax | Rs m | 3,870 | -65 | -5,921.5% | |
Gross profit margin | % | 27.6 | -7.8 | -351.1% | |
Effective tax rate | % | 24.8 | -3.4 | -722.5% | |
Net profit margin | % | 18.8 | -0.6 | -2,906.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,812 | 9,240 | 127.8% | |
Current liabilities | Rs m | 3,776 | 9,998 | 37.8% | |
Net working cap to sales | % | 39.1 | -7.5 | -520.6% | |
Current ratio | x | 3.1 | 0.9 | 338.4% | |
Inventory Days | Days | 77 | 46 | 167.1% | |
Debtors Days | Days | 82 | 60 | 136.1% | |
Net fixed assets | Rs m | 14,398 | 10,124 | 142.2% | |
Share capital | Rs m | 175 | 206 | 85.3% | |
"Free" reserves | Rs m | 22,277 | 5,582 | 399.1% | |
Net worth | Rs m | 22,452 | 7,734 | 290.3% | |
Long term debt | Rs m | 7 | 4,889 | 0.1% | |
Total assets | Rs m | 26,962 | 22,882 | 117.8% | |
Interest coverage | x | 444.3 | -0.3 | -136,596.5% | |
Debt to equity ratio | x | 0 | 0.6 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.4 | 172.9% | |
Return on assets | % | 14.4 | 11.8 | 122.4% | |
Return on equity | % | 17.2 | -0.8 | -2,039.6% | |
Return on capital | % | 23.0 | 22.3 | 102.9% | |
Exports to sales | % | 0 | 3.0 | 0.0% | |
Imports to sales | % | 0 | 0.4 | 0.0% | |
Exports (fob) | Rs m | NA | 307 | 0.0% | |
Imports (cif) | Rs m | NA | 43 | 0.0% | |
Fx inflow | Rs m | 10,682 | 307 | 3,483.9% | |
Fx outflow | Rs m | 2,102 | 125 | 1,677.5% | |
Net fx | Rs m | 8,580 | 181 | 4,732.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,748 | 11,754 | 31.9% | |
From Investments | Rs m | -2,228 | -561 | 397.5% | |
From Financial Activity | Rs m | -1,475 | -6,762 | 21.8% | |
Net Cashflow | Rs m | 45 | 4,432 | 1.0% |
Indian Promoters | % | 73.8 | 39.6 | 186.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.6 | 7.5 | 20.7% | |
FIIs | % | 7.6 | 16.8 | 45.2% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.0 | 36.1 | 47.1% | |
Shareholders | 20,968 | 16,479 | 127.2% | ||
Pledged promoter(s) holding | % | 4.4 | 77.6 | 5.7% |
Compare AJANTA PHARMA With: ALKEM LABORATORIES FRESENIUS KABI ONCO. J.B.CHEMICALS TORRENT PHARMA STRIDES PHARMA SCIENCE
Compare AJANTA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets nosedived and registered sharp losses in yesterday's volatile session following a strong second wave of Covid-19 in the country.
For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More